CN Stock MarketDetailed Quotes
301075 Tibet Duo Rui Pharmaceutical
- 16.53
- -0.30-1.78%
Market Closed Sep 13 15:00 CST
1.32BMarket Cap1102.00P/E (TTM)
17.05High16.52Low8.53KlotVolume16.83Open16.83Pre Close14.26MTurnover3.11%Turnover Ratio70.04P/E (Static)80.00MShares31.4652wk High1.79P/B453.31MFloat Cap12.4852wk Low20.20Limit Up27.42MShs Float53.80Historical High13.46Limit Down3.15%Amplitude12.48Historical Low0.13Dividend TTM16.72Avg Price4.34KlotAsk0.76%Div YieldTTM100Lot Size3.77KlotBid
Tibet Duo Rui Pharmaceutical Key Stats
All
YOY
| (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -11.75%150.38M | 0.48%78.46M | -16.64%334.3M | -18.59%246.26M | -7.91%170.39M | 7.13%78.09M | -24.28%401.05M | -23.70%302.49M | -24.14%185.04M | -40.23%72.89M |
| Operating revenue | -11.75%150.38M | 0.48%78.46M | -16.64%334.3M | -18.59%246.26M | -7.91%170.39M | 7.13%78.09M | -24.28%401.05M | -23.70%302.49M | -24.14%185.04M | -40.23%72.89M |
| Other operating revenue | --230.99K | ---- | 820.47%631.78K | ---- | --0 | ---- | --68.64K | ---- | --0 | ---- |
| Interest income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Commission income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Premiums earned | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Total operating cost | -0.48%162.26M | 2.98%84.41M | -14.90%330.58M | -17.05%239.58M | -9.76%163.04M | 12.19%81.96M | -16.62%388.45M | -16.66%288.84M | -13.27%180.67M | -28.67%73.05M |
| Operating cost | 87.61%91.84M | 72.44%47.49M | 13.88%105.13M | 12.22%71.79M | 51.62%48.95M | 185.80%27.54M | 53.01%92.32M | 60.35%63.97M | 32.64%32.29M | -19.25%9.64M |
| Operating tax surcharges | -41.35%1.05M | -42.88%397.39K | -16.57%3.87M | -22.28%2.77M | -19.62%1.79M | -13.69%695.75K | -29.55%4.64M | -33.15%3.56M | -35.46%2.23M | -51.22%806.07K |
| Operating expense | -48.44%42.98M | -42.02%22.64M | -29.88%161.85M | -30.53%122.84M | -27.68%83.36M | -17.80%39.05M | -29.34%230.82M | -29.76%176.83M | -24.36%115.27M | -36.22%47.5M |
| Administration expense | 4.30%19.78M | 17.01%10.72M | -3.95%40.28M | -12.69%30.85M | -24.61%18.96M | -28.91%9.16M | -12.83%41.94M | 13.44%35.33M | 37.68%25.15M | 33.07%12.88M |
| Financial expense | 108.25%200.69K | 111.40%150.34K | 41.13%-4.55M | 13.62%-3.42M | 31.32%-2.43M | 45.81%-1.32M | -8,907.29%-7.72M | -469.71%-3.96M | -577.99%-3.54M | -836.51%-2.43M |
| -Interest expense (Financial expense) | 84.35%2.77M | 71.13%1.41M | 128.80%3.11M | 126.48%2.32M | 289.36%1.5M | 388.44%825.47K | 15.42%1.36M | 9.15%1.03M | -40.26%385.43K | -42.20%169K |
| -Interest Income (Financial expense) | 17.07%-2.65M | 40.74%-1.28M | 16.94%-7.72M | -11.39%-5.8M | 22.60%-3.2M | 18.88%-2.15M | -698.13%-9.29M | -2,325.12%-5.21M | -3,374.06%-4.13M | -5,570.88%-2.65M |
| Research and development | -48.29%6.41M | -55.87%3.02M | -9.29%24M | 12.60%14.75M | 33.74%12.4M | 46.72%6.84M | 9.91%26.45M | -24.53%13.1M | 1.90%9.27M | 7.44%4.66M |
| Credit Impairment Loss | 113.48%257.98K | -669.82%-81.56K | 135.76%964.63K | 29.68%-1.97M | -1,492.71%-1.91M | -100.87%-10.59K | -98.85%-2.7M | -163.52%-2.8M | -52.18%137.43K | 599.27%1.22M |
| Asset Impairment Loss | 183.15%499.14K | ---2.45K | -192.54%-1.06M | -1,417.53%-774.62K | -256.01%-600.27K | ---- | -288.65%-362.97K | 582.48%58.79K | -4,234.66%-168.61K | ---- |
| Other net revenue | -31.81%5.03M | 61.82%2.45M | 113.31%18.47M | 13.46%13.46M | -33.58%7.37M | -84.17%1.51M | -10.35%8.66M | 233.89%11.86M | 126.46%11.1M | 124.50%9.55M |
| Fair value change income | --251.98K | ---- | --66K | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Invest income | 187.85%3.93M | 189.33%2.47M | 49,645.09%5.64M | 39.89%4.08M | 53.54%1.37M | --852.9K | 105.78%11.34K | --2.92M | --889.21K | ---- |
| Net open hedge income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| -Including: Investment income associates | 1,706.94%1.66M | 794.61%1.25M | 361.57%2.84M | --1.52M | ---103.51K | --140.12K | ---1.08M | ---- | --0 | ---- |
| Exchange income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Asset deal income | ---22.65K | ---- | --82.89K | --22.47K | ---- | ---- | ---- | ---- | --0 | ---- |
| Other revenue | -98.72%109.4K | -90.72%62.08K | 9.11%12.77M | 3.54%12.1M | -16.80%8.52M | -91.96%669.13K | 3.57%11.71M | 152.51%11.68M | 121.78%10.24M | 103.99%8.33M |
| Operating profit | -146.54%-6.85M | -48.18%-3.5M | 4.38%22.19M | -21.07%20.14M | -4.81%14.73M | -125.20%-2.36M | -71.04%21.26M | -52.24%25.51M | -61.84%15.47M | -60.55%9.38M |
| Add:Non operating Income | -51.38%322.16K | -95.13%1.77K | 3,360.89%625.75K | 1,824.92%751.77K | 2,399.85%662.59K | 413.39%36.26K | 38.43%18.08K | 951.18%39.05K | 889.00%26.51K | --7.06K |
| Less:Non operating expense | -70.92%107.4K | 2.19%3.96K | 126.06%564.09K | 198.03%468.95K | 240.78%369.28K | -33.57%3.88K | 80.86%249.53K | 57.23%157.35K | 8.28%108.36K | 162.84%5.84K |
| Total profit | -144.21%-6.64M | -50.33%-3.51M | 5.82%22.25M | -19.59%20.42M | -2.40%15.02M | -124.85%-2.33M | -71.31%21.02M | -52.37%25.4M | -61.95%15.39M | -60.54%9.38M |
| Less:Income tax cost | -28.30%1.16M | -63.10%69.76K | 111.27%5.16M | -27.03%2.77M | -31.07%1.61M | -77.97%189.04K | -67.09%2.44M | -37.15%3.79M | -49.58%2.34M | -69.22%858.09K |
| Net profit | SL-7.79M | FPtoL-3.57M | -8.03%17.09M | -18.28%17.65M | 2.74%13.41M | SL-2.52M | -71.78%18.58M | -54.31%21.6M | -63.55%13.05M | -59.39%8.52M |
| Net profit from continuing operation | -158.14%-7.79M | -41.82%-3.57M | -8.03%17.09M | -18.28%17.65M | 2.74%13.41M | -129.57%-2.52M | -71.78%18.58M | -54.31%21.6M | -63.55%13.05M | -59.39%8.52M |
| Less:Minority Profit | -371.20%-4.52M | -902.75%-1.04M | 8.30%-1.76M | -87.35%-1.66M | -22.64%-958.87K | 73.32%-103.48K | 27.54%-1.92M | 57.03%-884.37K | 38.41%-781.86K | 51.74%-387.92K |
| Net profit of parent company owners | -122.81%-3.28M | -4.97%-2.54M | -8.05%18.85M | -14.13%19.31M | 3.86%14.37M | -127.12%-2.42M | -70.07%20.5M | -54.43%22.49M | -62.69%13.83M | -59.10%8.91M |
| Earning per share | ||||||||||
| Basic earning per share | -122.22%-0.04 | 0.00%-0.03 | -7.69%0.24 | -14.29%0.24 | 5.88%0.18 | -127.27%-0.03 | -75.24%0.26 | -65.85%0.28 | -72.58%0.17 | -69.44%0.11 |
| Diluted earning per share | -122.22%-0.04 | 0.00%-0.03 | -7.69%0.24 | -14.29%0.24 | 5.88%0.18 | -127.27%-0.03 | -75.24%0.26 | -65.85%0.28 | -72.58%0.17 | -69.44%0.11 |
| Other composite income | 252.17%1.97M | 7.9M | 7.9M | 7.9M | -1.3M | |||||
| Other composite income of parent company owners | ---- | ---- | 252.17%1.97M | --7.9M | --7.9M | --7.9M | ---1.3M | ---- | ---- | ---- |
| Total composite income | -136.58%-7.79M | -166.44%-3.57M | 10.27%19.06M | 18.29%25.56M | 63.28%21.31M | -36.88%5.38M | -73.75%17.29M | -54.31%21.6M | -63.55%13.05M | -59.39%8.52M |
| Total composite income of parent company owners | -114.71%-3.28M | -146.27%-2.54M | 8.42%20.82M | 21.01%27.21M | 60.98%22.27M | -38.47%5.48M | -71.96%19.21M | -54.43%22.49M | -62.69%13.83M | -59.10%8.91M |
| Total composite income of minority owners | -371.20%-4.52M | -902.75%-1.04M | 8.30%-1.76M | -87.35%-1.66M | -22.64%-958.87K | 73.32%-103.48K | 27.54%-1.92M | 57.03%-884.37K | 38.41%-781.86K | 51.74%-387.92K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- |
| Auditor | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg
No Data